Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
CyPA Double Nickase Plasmid (h): sc-418155-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CyPA Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- CyPA Double Nickase Plasmid (h) and CyPA Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting PPIA. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CyPA Antibody (6-YD13): sc-134310
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CyPA Double Nickase Plasmid (h) | sc-418155-NIC | 20 µg | $410.00 | |||
CyPA Double Nickase Plasmid (h2) | sc-418155-NIC-2 | 20 µg | $410.00 |
PPIA encodes cyclophilin A (CyPA), a ubiquitous peptidyl-prolyl cis–trans isomerase that accelerates protein folding and conformational switching in the cytosol and nucleus. CyPA modulates proteostasis and stress-responsive signaling, including chaperone-associated pathways and regulation of kinase and transcription factor activities that influence apoptosis, inflammation, and cell-cycle progression. Through interactions with partners such as CD147/BSG and diverse client proteins, CyPA can shape leukocyte trafficking and oxidative stress responses, linking it to cardiovascular, neuroinflammatory, and tumor-associated processes. Altered PPIA expression or CyPA activity has been reported across multiple disease contexts, making it a useful target for mechanistic studies of signaling, protein homeostasis, and host–pathogen interactions.
CyPA Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the PPIA locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within PPIA. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt PPIA function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of PPIA-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.